not happy, page-32

Ok Had a long chat with Kym,
Points of discussions, Cantrixil only.
*Toxicology as a stand alone document is very good. Management and team are excited.
*Now the package is being assessed by the IFD and the SDA for final approval from the Ethics committee.
*Clinical trials on track for 2nd half of the year and management will formally ANN to the market once formal approval is given.
*The toxicology report as a stand alone is not leveraged in any shape way or form until approval is given. In other words the Ethics committee agrees with management that we are good to proceed to the clinic. Then the formal announcement will be submitted. Management do not want to be in a position to ANN toxicology report to the market only to have issues later. This is where management see a re rate. When the pre clinical package is approved.
*Manufacturing is being perused concurrently to these events aimed at the 2nd half year clinical phase 1 so to is the clinical managers preparing clinical protocols.
*3rd party approval here is the key, until then we wait. Management are confident and still on track to have both manufacturing and clinical commissioning in readiness upon approval.
*Until then the company website and emailed updates is the tool to access research. (Not sure whether this is the right marketing strategy to entice new investor.)

Hope I make sense. Looking forward to the next 6 months again.
cheers.
M